Lilly International Head Says To Reuters Global Markets Forum: "We're Trying To Build Up As Much Capacity As We Can" For Tirzepatide; Lilly's Yuffa Says Mounjaro Expansions Depend On Regulatory Approvals, Reimbursement, Sufficient Supplies To GMF
Portfolio Pulse from Benzinga Newsdesk
The head of Lilly International spoke at the Reuters Global Markets Forum, indicating efforts to increase capacity for Tirzepatide, a drug also known as Mounjaro. The expansion of Mounjaro is contingent on regulatory approvals, reimbursement, and adequate supplies. The discussion took place at Davos, as reported by Reuters.
January 16, 2024 | 3:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lilly International is focusing on increasing the production capacity for Tirzepatide, known as Mounjaro, which may lead to revenue growth if regulatory approvals and reimbursements are secured.
The statement from Lilly International's head suggests a proactive approach to scaling up production for Tirzepatide, anticipating future demand. This could positively impact LLY's stock as it may lead to increased sales and market penetration, assuming regulatory and reimbursement hurdles are cleared. The confidence score reflects the dependency on external factors such as regulatory decisions and supply chain management.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100